Please login to the form below
Cardax adds big pharma experience to board
Brings in former Novartis, BMS and Boehringer executives
Hawaii-based anti-inflammatory specialist Cardax has added three new members to its board, each with experience at a major pharma company.
George Bickerstaff is a former chief financial officer of Novartis who is now managing director at investment bank MM Dillon. He was also chief financial officer at IMS Health.
Tamar Howson (pictured right) is a former senior business development executive at Bristol-Myers Squibb and SmithKline Beecham (now GSK) who now acts as an independent consultant to life sciences companies.
The final new addition is Terence Kelly who provides Cardax with scientific experience having served as VP, department of medicinal chemistry at Boehringer Ingelheim. He is currently president and CEO of CoMentis, a private biotech company focused on neurodegenerative diseases.
“The distinctive, yet complementary skills of our new board members provide a strong foundation as we develop and commercialise our nutraceutical and pharmaceutical programmes,” said David Watumull, president and CEO of Cardax.
These programmes are focused on developing products that are as effective as steroids and NSAIDS but have safer profiles.
Subscribe to our email news alerts
- Actinic keratosis – a common skin condition that can lead to skin cancer
- The paper trail
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
No results were found
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
